Journal of Clinical Endocrinology & Metabolism, Vol 81, 3360-3365, Copyright © 1996 by Endocrine Society

ARTICLES

ret/PTC-1, -2, and -3 oncogene rearrangements in human thyroid carcinomas: implications for metastatic potential?

SL Sugg, L Zheng, IB Rosen, JL Freeman, S Ezzat and SL Asa
Department of Surgery, University of Toronto, Ontario, Canada.

The ret/PTC oncogene is unique to papillary thyroid cancer. Three forms of this oncogene, formed by translocation of three different genes to the tyrosine kinase domain of the ret protooncogene, result in constitutive kinase activation. Correlation with clinical outcome is controversial; ret/PTC-1 has been suggested to predict aggressive behavior. There is no morphological description of ret/PTC-positive tumors. We analyzed 60 thyroid carcinomas for ret/PTC expression to determine correlation with clinical history, disease stage, or tumor morphology. Ribonucleic acid extracted from frozen tissue was reverse transcribed; PCR was performed to amplify ret/PTC-1, 2, and -3. The TPC- 1 cell line was the positive control for ret/PTC-1. All tumors were characterized morphologically. Clinical data were collected. The 57 papillary and 3 follicular carcinomas were resected from 44 female patients and 15 males. The average age at diagnosis was 46.2 yr (range. 24-83 yr). Three patients had a history of neck irradiation. At diagnosis, 11 patients had extrathyroidal tumor extension, 20 had lymph node metastases, and 1 had lung metastasis. Thirteen patients had tall cell papillary carcinomas; 3 tumors had focal insular or anaplastic dedifferentiation. The average follow-up was 13.4 months, during which 4 patients had recurrent disease. No deaths occurred. One papillary carcinoma (1.7%) was positive for ret/PTC-1, none was positive for ret/PTC-2, and 2(3.4%) were positive for ret/PTC-3. Although all 3 patients who had tumors containing ret/PTC rearrangements were under the age of 45 yr (range, 26-44 yr) and had small tumors (< 1.2 cm), 2 of these 3 patients presented with lymph node metastases, and the third had lymphatic invasion. ret/PTC oncogene expression did not correlate with radiation history. In summary, ret/PTC oncogene rearrangements were found in 3 of 60 (5%) thyroid carcinomas and were not present in tumors with aggressive morphological features. However, we found ret/PTC rearrangements in young patients (< 45 yr of age) with small thyroid carcinomas showing a predisposition for lymphatic involvement, suggesting a possible role in the development of this subgroup of tumors.

This article has been cited by other articles:

				E. Roti, E. C degli Uberti, M. Bondanelli, and L. E Braverman Thyroid papillary microcarcinoma: a descriptive and meta-analysis study Eur. J. Endocrinol., December 1, 2008; 159(6): 659 - 673. [Abstract] [Full Text] [PDF]

				Z. Zhu, R. Ciampi, M. N. Nikiforova, M. Gandhi, and Y. E. Nikiforov Prevalence of RET/PTC Rearrangements in Thyroid Papillary Carcinomas: Effects of the Detection Methods and Genetic Heterogeneity J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3603 - 3610. [Abstract] [Full Text] [PDF]

				E. Roti, R. Rossi, G. Trasforini, F. Bertelli, M. R. Ambrosio, L. Busutti, E. N. Pearce, L. E. Braverman, and E. C. degli Uberti Clinical and Histological Characteristics of Papillary Thyroid Microcarcinoma: Results of a Retrospective Study in 243 Patients J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2171 - 2178. [Abstract] [Full Text] [PDF]

				B Jarzab, D Handkiewicz-Junak, and J Wloch Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review Endocr. Relat. Cancer, December 1, 2005; 12(4): 773 - 803. [Abstract] [Full Text] [PDF]

				C. Martins, B. Cavaco, G. Tonon, F. J. Kaye, J. Soares, and I. Fonseca A Study of MECT1-MAML2 in Mucoepidermoid Carcinoma and Warthin's Tumor of Salivary Glands J. Mol. Diagn., August 1, 2004; 6(3): 205 - 210. [Abstract] [Full Text]

				S. Sadetzki, R. Calderon-Margalit, B. Modan, S. Srivastava, and R. M. Tuttle Ret/PTC Activation in Benign and Malignant Thyroid Tumors Arising in a Population Exposed to Low-Dose External-Beam Irradiation in Childhood J. Clin. Endocrinol. Metab., May 1, 2004; 89(5): 2281 - 2289. [Abstract] [Full Text] [PDF]

				A. R. Marques, C. Espadinha, A. L. Catarino, S. Moniz, T. Pereira, L. G. Sobrinho, and V. Leite Expression of PAX8-PPAR{gamma}1 Rearrangements in Both Follicular Thyroid Carcinomas and Adenomas J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3947 - 3952. [Abstract] [Full Text] [PDF]

				G. Belchetz, C. C. Cheung, J. Freeman, I. B. Rosen, I. J. Witterick, and S. L. Asa Hurthle Cell Tumors: Using Molecular Techniques to Define a Novel Classification System Arch Otolaryngol Head Neck Surg, March 1, 2002; 128(3): 237 - 240. [Abstract] [Full Text] [PDF]

				G. Chiappetta, P. Toti, F. Cetta, A. Giuliano, F. Pentimalli, I. Amendola, S. Lazzi, M. Monaco, L. Mazzuchelli, P. Tosi, et al. The RET/PTC Oncogene Is Frequently Activated in Oncocytic Thyroid Tumors (Hurthle Cell Adenomas and Carcinomas), but Not in Oncocytic Hyperplastic Lesions J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 364 - 369. [Abstract] [Full Text] [PDF]

				M. Santoro, M. Papotti, G. Chiappetta, G. Garcia-Rostan, M. Volante, C. Johnson, R. L. Camp, F. Pentimalli, C. Monaco, A. Herrero, et al. RET Activation and Clinicopathologic Features in Poorly Differentiated Thyroid Tumors J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 370 - 379. [Abstract] [Full Text] [PDF]

				E. L. Chua, W. M. Wu, K. T. Tran, S. W. McCarthy, C. S. Lauer, D. Dubourdieu, N. Packham, C. J. O’Brien, J. R. Turtle, and Q. Dong Prevalence and Distribution of ret/ptc 1, 2, and 3 in Papillary Thyroid Carcinoma in New Caledonia and Australia J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2733 - 2739. [Abstract] [Full Text]

				O. M. Sheils, J. J. O'Leary, V. Uhlmann, K. Luttich, and E. C. Sweeney ret/PTC-1 Activation in Hashimoto Thyroiditis International Journal of Surgical Pathology, July 1, 2000; 8(3): 185 - 189. [Abstract] [PDF]

				H. M. Rabes, E. P. Demidchik, J. D. Sidorow, E. Lengfelder, C. Beimfohr, D. Hoelzel, and S. Klugbauer Pattern of Radiation-induced RET and NTRK1 Rearrangements in 191 Post-Chernobyl Papillary Thyroid Carcinomas: Biological, Phenotypic, and Clinical Implications Clin. Cancer Res., March 1, 2000; 6(3): 1093 - 1103. [Abstract] [Full Text]

				C. C. Cheung, S. Ezzat, L. Ramyar, J. L. Freeman, and S. L. Asa Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 878 - 882. [Abstract] [Full Text]

				F. Cetta, M. Gori, N. Raffaelli, C. Baldi, G. Montalto, D. L Learoyd, and B. G Robinson RET/PTC and RET Tyrosine Kinase Expression in Adult Papillary Thyroid Carcinomas--Authors' Response J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2258 - 2258. [Full Text]

				F. Cetta, M. Gori, N. Raffaelli, C. Baldi, and G. Montalto Comment on Clinical and Prognostic Relevance of Ret-PTC Activation in Patients with Papillary Thyroid Carcinoma J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2257a - 2258. [Full Text]

				C. Soravia, S. L. Sugg, T. Berk, A. Mitri, H. Cheng, S. Gallinger, Z. Cohen, S. L. Asa, and B. V. Bapat Familial Adenomatous Polyposis-Associated Thyroid Cancer : A Clinical, Pathological, and Molecular Genetics Study Am. J. Pathol., January 1, 1999; 154(1): 127 - 135. [Abstract] [Full Text] [PDF]

				S. L. Sugg, S. Ezzat, I. B. Rosen, J. L. Freeman, and S. L. Asa Distinct Multiple RET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia J. Clin. Endocrinol. Metab., November 1, 1998; 83(11): 4116 - 4122. [Abstract] [Full Text]

				C.-H. Lee, L.-S. Hsu, C.-W. Chi, G.-D. Chen, A.-H. Yang, and J.-Y. Chen High Frequency of Rearrangement of the RET Protooncogene (RET/PTC) in Chinese Papillary Thyroid Carcinomas J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1629 - 1632. [Abstract] [Full Text]

				B. Mayr, M. D., G. Brabant, M. D., P. Goretzki, M. D, H. Dralle, and M. D. ret/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential? J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1306 - 1306. [Full Text] [PDF]